BioSpecifics Technologies (BSTC) Stock Price, News & Analysis

Company Overview

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Key Stats

• Today's Range: $88.53 to $88.53
• 50-Day Range: $88.22 to $88.53
• 52-Week Range: $42.00 to $89.15
• Volume: N/A
• Average Volume: 61,105 shs
• Market Capitalization: $650.25 million
• P/E Ratio: 37.51
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BSTC Stock Analysis - Frequently Asked Questions

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to the consensus estimate of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a trailing twelve-month return on equity of 14.81%.

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioSpecifics Technologies investors own include Bristol Myers Squibb (BMY), AbbVie (ABBV), Biogen (BIIB), Pfizer (PFE), Intel (INTC), Johnson & Johnson (JNJ) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/14/2020
• Today: 10/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BSTC
• CIK: 875622
• Web: www.biospecifics.com
• Phone: 302-842-8450
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $3.33
• Trailing P/E Ratio: 37.51
• Forward P/E Ratio: 61.91
• P/E Growth: N/A
• Net Income: $24.47 million
• Net Margins: 47.43%
• Pretax Margin: N/A
• Return on Equity: 14.81%
• Return on Assets: 14.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 66.24
• Quick Ratio: 66.24

Sales & Book Value

• Annual Sales: $38.19 million
• Price / Sales: 17.03
• Cash Flow: $3.38 per share
• Price / Cash Flow: 26.18
• Book Value: $18.42 per share
• Price / Book: 4.81

Miscellaneous

• Outstanding Shares: 7,345,000
• Free Float: N/A
• Market Cap: $650.25 million
• Optionable: Not Optionable
• Beta: 0.24